CARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7 USD | +4.23% |
|
+1.45% | -5.79% |
Presenter SpeechDaniel Wolle (Analysts)Welcome, everyone. We're continuing the 40th JPM confer...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7
USD
Average target price
5.12
USD
Spread / Average Target
+631.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.79% | 38.27M | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.70% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.49% | 8.75B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Transcript : Cara Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 11
